Status:
COMPLETED
OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to characterize the plasma pharmacokinetics of two formulations of PF 05221304 in healthy adults.
Eligibility Criteria
Inclusion
- Ages of 18 and 55 years old inclusive
- Body Mass Index (BMI) of \>= 17.5 and \<= 30.4 kg/m2
- Total body weight \> 50 kg (110lb)
Exclusion
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, allergic disease or clinical findings
Key Trial Info
Start Date :
March 13 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 8 2019
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03871439
Start Date
March 13 2019
End Date
May 8 2019
Last Update
May 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer New Haven Clinical Research Unit
New Haven, Connecticut, United States, 06511